📝 SummarXiv

Abstract

O-GlcNAcylation, a subtype of glycosylation, has the potential to be an important target for therapeutics, but methods to reliably predict O-GlcNAcylation sites had not been available until 2023; a 2021 review correctly noted that published models were insufficient and failed to generalize. Moreover, many are no longer usable. In 2023, a considerably better recurrent neural network (RNN) model was published. This article creates improved models by using a new loss function, which we call the weighted focal differentiable MCC. RNN models trained with this new loss display superior performance to models trained using the weighted cross-entropy loss; this new function can also be used to fine-tune trained models. An RNN trained with this loss achieves state-of-the-art performance in O-GlcNAcylation site prediction with an F$_1$ score of 38.88% and an MCC of 38.20% on an independent test set from the largest dataset available.